First FDA-approved vaccine for the prevention of dengue disease in endemic regions

May 4, 2019

healthysoch

New Delhi, May 04, 2019 :

The U.S. Food and Drug Administration announced the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.

The first infection with dengue virus typically results in either no symptoms or a mild illness that can be mistaken for the flu or another viral infection. A subsequent infection can lead to severe dengue, including dengue hemorrhagic fever (DHF), a more severe form of the disease that can be fatal. Symptoms may include stomach pain, persistent vomiting, bleeding, confusion and difficulty breathing. Approximately 95 percent of all severe/hospitalized cases of dengue are associated with second dengue virus infection.

“Infection by one type of dengue virus usually provides immunity against that specific serotype, but a subsequent infection by any of the other three serotypes of the virus increases the risk of developing severe dengue disease, which may lead to hospitalization or even death.

Dengvaxia is not approved for use in individuals not previously infected by any dengue virus serotype or for whom this information is unknown.

This is because in people who have not been infected with dengue virus, Dengvaxia appears to act like a first dengue infection – without actually infecting the person with wild-type dengue virus – such that a subsequent infection can result in severe dengue disease.

Dengvaxia is a live, attenuated vaccine that is administered as three separate injections, with the initial dose followed by two additional shots given six and twelve months later.

The FDA granted this application Priority Reviewand a Tropical Disease Priority Review Voucherunder a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases. The approval was granted to Sanofi Pasteur.

The Author of this article is Dr K K Aggarwal, Padma Shri Awardee

healthy soch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

First ever International Conference cum Exhibition on AYUSH and Wellness inaugurated in New Delhi today 

First ever International Conference cum Exhibition on AYUSH and Wellness inaugurated in New Delhi today 

1500 delegates from 60 countries and 250 manufacturers of alternative

Capacity building for developing Trauma Care Facilities on National Highways

New Delhi, February 05, 2019: Under the scheme ‘Assistance for Capacity